You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Emerging Pathways in Advanced Cholangiocarcinoma

  • Authors: Milind Javle, MD; Tin-Yun Tang, MD; Arndt Vogel, MD; Rachna Shroff, MD, MS
  • CME / ABIM MOC Released: 3/11/2022
  • Valid for credit through: 3/11/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, gastroenterologists, pathologists, and other healthcare providers caring for patients with cholangiocarcinoma (CCA)

The goal of this activity is for learners to better understand biomarker testing in patients with CCA, mechanisms of action (MOAs) of emerging treatment pathways, and the efficacy and safety of new agents.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Biomarker expression within CCA
    • MOAs of novel agents in CCA
  • Have greater competence related to
    • Testing for biomarkers within CCA
  • Demonstrate greater confidence in their ability to
    • Understand the side effects of targeted therapies used to manage CCA


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Milind Javle, MD

    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosures

    Disclosure: Milind Javle, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Bristol Myers Squibb; EMD Serono; Meclun; Taiho; TransThera; QED
    Speaker or a member of a speakers bureau for: Agios; Incyte Corporation; QED
    Grants for clinical research from: Agios; Aslan; AstraZeneca; Basilea; EMD Serono; Eli Lilly; Incyte Corporation; Merck; Novartis; QED
    Other: Steering committee: Incyte Corporation; NuCana; PCI

  • Tin-Yun Tang, MD

    Hematology/Oncology Fellow
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosures

    Disclosure: Tin-Yun Tang, MD, has the following relevant financial relationships:
    Stocks, stock options, or bonds from: Invitae, Editas, UniQure

  • Arndt Vogel, MD

    Professor
    Medical School Hannover
    Hannover, Germany

    Disclosures

    Disclosure: Arndt Vogel, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Bayer; Bristol Meyers Squibb; BTG; Eisai; GlaxoSmithKline; Imaging Equipment Ltd (AAA); Incyte Corporation; Ipsen; Lilly; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Servier; Sirtex; Terumo
    Speaker or a member of a speakers bureau for: AstraZeneca; Bayer; Bristol Myers Squibb; BTG; Eisai; GlaxoSmithKline; Imaging Equipment Ltd (AAA); Incyte Corporation; Ipsen; Lilly; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Servier; Sirtex; Terumo
    Grants for clinical research from: Servier

  • Rachna Shroff, MD, MS

    Associate Professor, Medicine
    College of Medicine Tucson
    Chief, Section of GI Medical Oncology
    Director, UACC Clinical Trials Office
    Associate Dean, Clinical and Translational Research
    The University of Arizona Health Sciences
    Tucson, Arizona, United States

    Disclosures

    Disclosure: Rachna Shroff, MD, MS, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Incyte Corporation, Merck, QED, Servier, Taiho, Zymeworks
    Speaker or a member of a speakers bureau for: Servier
    Grants for clinical research from: Bayer, Bristol Myers Squibb, Exelixis, IMV Inc., LOXO, Novocure, NUCANA, QED, Rafael Pharm, SeaGen Inc., formerly Seattle Genetics, Inc., Taiho

Editors

  • Davecia Ragoonath Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Davecia Ragoonath Cameron, MS, has disclosed no relevant financial relationships.

  • Jenny Engelmoer, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Jenny Engelmoer, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Emerging Pathways in Advanced Cholangiocarcinoma

Authors: Milind Javle, MD; Tin-Yun Tang, MD; Arndt Vogel, MD; Rachna Shroff, MD, MSFaculty and Disclosures

CME / ABIM MOC Released: 3/11/2022

Valid for credit through: 3/11/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Biomarkers for Advanced Cholangiocarcinoma

Dr Javle and Dr Tang provide insight on biomarkers and their importance in advanced cholangiocarcinoma (CCA).
Milind M. Javle, MD; Tin-Yun Tang, MD

Mechanism of Action of the Different Pathways

Dr Vogel discusses the various mechanisms of action using fun animations.
Arndt Vogel, MD

Safety and Efficacy of Therapeutic Agents for Advanced CCA

Dr Shroff delves into the data regarding therapies for advanced CCA.
Rachna Shroff, MD, MS
 

Educational Impact Challenge

The goal of this activity is for learners to better understand biomarker testing in patients with CCA, mechanisms of action (MOAs) of emerging treatment pathways, and the efficacy and safety of new agents.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print